HLA‐DQA1‐HLA‐DRB1 polymorphism is a major predictor of azathioprine‐induced pancreatitis in patients with inflammatory bowel disease

• Published in: Alimentary pharmacology & therapeutics Vol. 47; no. 5; pp. 615 - 620
• Main Authors: Wilson, A., Jansen, L. E., Rose, R. V., Gregor, J. C., Ponich, T., Chande, N., Khanna, R., Yan, B., Jairath, V., Khanna, N., Sey, M., Beaton, M., McIntosh, K., Teft, W. A., Kim, R. B.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.03.2018
• Subjects: 6-Mercaptopurine; Adult; Azathioprine; Azathioprine - adverse effects; Azathioprine - therapeutic use; Canada; Case-Control Studies; Clinical medicine; Cohort Studies; DQA1 protein; Drb1 protein; Female; Gene polymorphism; Genome-wide association studies; Genome-Wide Association Study; Genomes; Genotype; Genotypes; Haplotypes; Histocompatibility antigen HLA; HLA-DQ alpha-Chains - genetics; HLA-DRB1 Chains - genetics; Humans; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - genetics; Intestine; Male; Middle Aged; Pancreatitis; Pancreatitis - chemically induced; Pancreatitis - genetics; Pharmacogenetics; Pharmacogenomics; Polymorphism, Single Nucleotide; Retrospective Studies; Single-nucleotide polymorphism; Canada

Summary Background Azathioprine (AZA)‐induced pancreatitis is an unpredictable and dose‐independent adverse event affecting 2%‐7% of patients with inflammatory bowel disease (IBD) patients treated with AZA. There are no tools in clinical practice to identify at‐risk individuals; however, a genome wi...